List view / Grid view
7 March 2013 | By Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role…
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
6 March 2013 | By Roche
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies...
5 March 2013 | By Gilead Sciences
TAF-based regimen now in Phase 3 development...
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
5 March 2013 | By Roche
Roche to inform about plans for succession in autumn 2013...
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
4 March 2013 | By Biogen Idec
“We are encouraged by the FDA’s acceptance of our application..."
4 March 2013 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the following organizational changes taking place from April 1, 2013...
3 March 2013 | By University of Mississippi
A baby born with the virus that causes AIDS appears to have been cured, scientists announced Sunday...
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
1 March 2013 | By Edelman (On behalf of PerkinElmer)
Revolutionaries for Global Health Summit, 5 -6 March 2013, Brussels...
